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The use of tyrosine kinase inhibitors (TKIs) has dramati-
cally improved outcomes for patients with chronic mye-
loid leukemia (CML). The IRIS study is the definitive
phase III trial of imatinib mesylate as frontline therapy for
CML. Seven year follow-up data has recently been
reported [1]. The overall survival (including deaths from
all causes) is 86% and the event free survival is 81% at
seven years. Seven percent of patients have progressed to
accelerated or blastic phase, with the highest risk being in
the second year of treatment. Eighty-two percent of
patients have achieved complete cytogenetic remission
(CCyR) and 83% of these patients maintain that remis-
sion. Of the patients that discontinued study, 8% were for
toxicity, 15% for efficacy and 17% for other reasons.
In the United States, the FDA approved dose of imatinib
for patients in chronic phase is 400 mg daily. However in
the original phase I study a true MTD was not determined,
and the 400 mg dose was chosen because it was biologi-
cally active. More recent data suggests that higher doses
may be more efficacious. In the TOPS Trial newly diag-
nosed patients received either 400 or 800 mg imatinib as
front line therapy [2]. The primary endpoint of the study,
major molecular remission (MMR) at 12 months, was
similar in the two arms. However patients receiving imat-
inib 800 mg daily achieved complete molecular remission
(CMR) faster (8.4 months versus 13.6 months, respec-
tively, p = 0.0038) than patients receiving 400 mg of imat-
inib daily. The Central European Leukemia Study Group
performed a similar study, the ISTAHIT study, in which
previously treated patients (with agents other than TKIs)
received imatinib 800 mg daily versus 400 mg daily for
the first 6 months of therapy [3]. After that all patients
received 400 mg daily. This study demonstrated that
patients receiving imatinib 800 mg achieved a MMR and/
or CCyR faster than patients receiving imatinib 400 mg.
Another study of high dose versus standard dose imatinib
failed to show a statistically significant increase in the per-
centage of patients achieving MMR [4]. However when
patients were analyzed in terms of the dose of imatinib
they actually received, the CCyR was 91% for patients
receiving 700–800 mg of imatinib, 73% for patients
receiving 400–699 mg and only 20% for patients receiv-
ing less than 400 mg of imatinib. Whether the faster
achievement of MMR will translate into improved long
term outcome remains to be determined. When time to
response was measured on the German CML Study IV,
achievement of MMR by 18 months was a strong predictor
of event free survival [5]. Similarly, in a retrospective study
from Australia, the early achievement of molecular
response was predictive of event free survival [6]. Events
occurred in 0/41 patients achieving MMR by 6 months, 3/
40 (8%) of patients achieving MMR in 6–12 months, and
5/22 (15%) of patients achieving MMR by 12–18 months.
Prior to imatinib, interferon and ara-C were the mainstays
of therapy. The SPIRIT Trial is studying whether the addi-
tion of ara-C or pegylated interferon to imatinib will result
in an increased percentage of patients with MMR [7].
Although many patients were unable to tolerate the
increased toxicity of the combination therapy, the per-
centage of patients with MMR was 57% for patients rand-
omized to imatinib plus pegylated interferon versus 38%
for patients randomized to imatinib 400 mg as a single
agent, p = 0.0008. Again, whether this translates into
improved long term outcome remains to be determined.
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ond line therapy with either nilotinib or dasatinib. Nilo-
tinib is an imatinib analogue with more specific BCR/ABL
binding. Dasatinib is a dual SRC/ABL kinase inhibitor.
Both are effective against a large number of BCR/ABL
kinase mutations with the exception of the T315I muta-
tion. Newer studies are evaluating the efficacy of these
agents in the front line setting [8,9]. Both agents lead to
high rates of CCyR at 12 months (nilotinib: 93%, dasat-
inib: 95%, imatinib historical control: 65%, respectively),
and MMR at 18 months (nilotinib: 65%, dasatinib: 48%,
respectively). Dasatinib toxicity includes pleural effusions
in 20% of patients and hemorrhage even in the absence of
thrombocytopenia. A change in the dose and schedule of
dasatinib to 100 mg orally daily has resulted in a decrease
in these toxicities with the maintenance of efficacy.
Patients receiving nilotinib require monitoring of QTc,
potassium and magnesium to prevent arrhythmias. Fur-
ther follow up is needed before these agents will be con-
sidered standard frontline therapy.
An important question is whether patients with CML can
be cured with imatinib. Early reports of pregnant women
discontinuing imatinib noted a very high rate of relapse.
A more formal study allowed patients who had been in
CMR for at least 2 years to stop imatinib [10]. Although
half of the patients relapsed rapidly, many of the patients
remain in CMR without further therapy. Interestingly,
there was trend towards a lower relapse rate in patients
who had exposure to interferon prior to imatinib. Most of
the patients who relapsed were sensitive to retreatment to
imatinib. However it is too early to recommend the dis-
continuation of imatinib outside of a clinical trial.
A number of new agents are currently under study. Bosuti-
nib is a dual ABL/SRC kinase inhibitor that has minimal
inhibition of PDGFR and c-kit. This agent leads to high
rates of major cytogenetic and MMR in patients with CML-
CP who are imatinib intolerant (51% and 39%, respec-
tively) or resistant (45% and 42%, respectively) [11].
Bosutinib also yields major cytogenetic remissions and
MMR in patients who have resistant to both imatinib and
dasatinib. Toxicity includes myelosuppression as well as
elevations in amylase and lipase. Patients with T315I
mutations remain a treatment challenge. Options include
aurora kinase inhibitors and allogeneic stem cell trans-
plantation. Omacetaxine mepesuccinate (homohar-
ringtonine) is also being studied [12]. In the past the
development of this agent was limited by toxicity, includ-
ing myelosuppression and the need for prolonged intrave-
nous administration to avoid hypotension. Recently a
subcutaneous formulation has been studied in patients
with T315I mutations. Complete hematologic remission
was seen in 80% of patients in chronic phase and 18% of
patients with accelerated phase CML. Toxicity included
myelosuppression and febrile neutropenia.
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